Carmofur

Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA) . Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) [1][2][3].

Product Specifications

CAS Number

[61422-45-5]

Product Name Alternative

HCFU

UNSPSC

12352005

Hazard Statement

H301, H361

Target

Ceramidase; FAAH; Glutathione Peroxidase; Nucleoside Antimetabolite/Analog; SARS-CoV; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/carmofur.html

Purity

99.95

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

O=C(N(C(N1)=O)C=C(F)C1=O)NCCCCCC

Molecular Formula

C11H16FN3O3

Molecular Weight

257.26

Precautions

H301, H361

References & Citations

[1]Jin Z, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020 Jun;27 (6) :529-532.|[2]Realini N, Solorzano C, Pagliuca C, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity[J]. Scientific reports, 2013, 3 (1) : 1035.|[3]Wu K, et al. A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS) -induced acute lung injury via inhibition of FAAH and NAAA activities[J]. Frontiers in pharmacology, 2019, 10: 818.